Axon Steven 4
4 · Apellis Pharmaceuticals, Inc. · Filed Feb 21, 2018
Insider Transaction Report
Form 4
Axon Steven
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2018-02-20$2.59/sh+38,610$100,000→ 38,610 total - Award
Stock Option (right to buy)
2018-02-16+60,000→ 60,000 totalExercise: $14.95Exp: 2028-02-15→ Common Stock (60,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2018-02-20+38,610→ 359,889 totalExercise: $2.59Exp: 2027-05-17→ Common Stock (38,610 underlying)
Footnotes (2)
- [F1]This option was granted on February 16, 2018 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
- [F2]This option was granted on May 18, 2017 and has vested as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service.